Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
$410.77
+5.46+1.35%
After hours$412.82+0.50%
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31.67B | 37.26B | 41.96B | 48.31B | 53.67B |
| Gross profit | 18.76B | 21.53B | 23.9B | 26.46B | 32.34B |
| Operating income | 6.26B | 7.62B | 7.85B | 9.58B | 11.72B |
| Net income | 4.88B | 5.63B | 6.17B | 5.78B | 7.65B |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief